Selected data models

You must log in to select data models for download or further analysis.

7 Search results.
Relevance Rating New first Old first

SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36) CRFs Roche FVF4170G Macular Edema NCT00473382

- 9/20/21 - 1 form, 7 itemgroups, 40 items, 1 language
Itemgroups: Patient administration, SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36), Adverse Event, Serious AE, Relevant Diagnostic Tests Performed, Tests, Additional Case Details:
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36) CRFs Roche FVF4168G Macular Edema NCT00473330

- 9/20/21 - 1 form, 7 itemgroups, 40 items, 1 language
Itemgroups: Patient administration, SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36), Adverse Event, Serious AE, Relevant Diagnostic Tests Performed, Tests, Additional Case Details:
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Efficacy of Formulation X and AVANDIA in Subjects with Type 2 Diabetes Mellitus 100723 - Additional Forms - Adverse Event

- 2/8/18 - 1 form, 1 itemgroup, 17 items, 1 language
Itemgroup: Adverse Event
Study ID: 100723 Clinical Study ID: AXR100723 Study Title: A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Compare the Efficacy of Formulation X and AVANDIA™ (8mg OD) in Subjects with Type 2 Diabetes Mellitus Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia; Avandia XR; Avandia XR,Rosiglitazone XR,Avandia; Rosiglitazone XR Study Indication: Diabetes Mellitus, Type 2 Documentation part: Additional Forms - Adverse Event

NON-SERIOUS ADVERSE EVENT REPORTING (MONTH 13 - MONTH 24) CRFs Roche FVF4170G Macular Edema NCT00473382

- 6/25/17 - 1 form, 3 itemgroups, 23 items, 1 language
Itemgroups: Patient administration, NON-SERIOUS ADVERSE EVENT REPORTING, Adverse Event
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

NON-SERIOUS ADVERSE EVENT REPORTING (MONTH 13 - MONTH 24) CRFs Roche FVF4168G Macular Edema NCT00473330

- 6/25/17 - 1 form, 3 itemgroups, 23 items, 1 language
Itemgroups: Patient administration, NON-SERIOUS ADVERSE EVENT REPORTING, Adverse Event
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

NON-SERIOUS ADVERSE EVENT REPORTING (DAY 0 - MONTH 12) INVESTIGATOR / SITE INFORMATION (SCREENING) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 6/25/17 - 1 form, 3 itemgroups, 23 items, 1 language
Itemgroups: Patient administration, NON-SERIOUS ADVERSE EVENT REPORTING, Adverse Event
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

NON-SERIOUS ADVERSE EVENT REPORTING (DAY 0 - MONTH 12) CRFs Roche FVF4168G Macular Edema NCT00473330

- 6/25/17 - 1 form, 3 itemgroups, 23 items, 1 language
Itemgroups: Patient administration, NON-SERIOUS ADVERSE EVENT REPORTING, Adverse Event
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial